Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
Remarks:
Type of genotoxicity: chromosome aberration
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: No OECD Guideline defined.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1991
Report date:
1991

Materials and methods

Principles of method if other than guideline:
Method: other
GLP compliance:
yes
Type of assay:
micronucleus assay

Test material

Constituent 1
Chemical structure
Reference substance name:
3-chlorophenyl isocyanate
EC Number:
220-822-5
EC Name:
3-chlorophenyl isocyanate
Cas Number:
2909-38-8
Molecular formula:
C7H4ClNO
IUPAC Name:
1-chloro-3-isocyanatobenzene
Details on test material:
Purity: 99.8%, clear liquid, molecular weight: 153.6.

Test animals

Species:
mouse
Strain:
other: Bor: NMRI
Sex:
male/female

Administration / exposure

Route of administration:
intraperitoneal
Duration of treatment / exposure:
single administration
Frequency of treatment:
single administration
Post exposure period:
Animals were sacrificed 16, 24 and 48 hours after the administration and femoral bone marrow was prepared.
Doses / concentrations
Remarks:
Doses / Concentrations:
50 and 20 mg/kg
Basis:

No. of animals per sex per dose:
no data
Control animals:
not specified

Examinations

Tissues and cell types examined:
femoral bone marrow.

Results and discussion

Test results
Sex:
male/female
Genotoxicity:
negative
Toxicity:
yes
Vehicle controls validity:
not specified
Negative controls validity:
valid
Positive controls validity:
valid

Any other information on results incl. tables

After single intraperitoneal administration of 50 mg/kg test substance, treated animals showed the following compound-related symptoms until sacrifice: apathy, streching of body, roughened fur, blue discoloration of end of tail, spasm, twitching, shivering, difficulty in breathing, eyelids stuck together and reduced excretion. Their feeding behavior was normal. Two of 40 treated animals died during the test period, due to the acute toxicity of 50 mg/kg test substance. The abdomen of these animals was filled with a clear liquid. White spots were found on the organs in the surrounding of the injection site.

Applicant's summary and conclusion

Executive summary:

The micronucleus test was employed to investigate the test substance in male and female mice for a possible clastogenic effect on the chromosomes of bone-marrow erythroblasts. The known clastogen and cytostatic agent, cyclophosphamide, served as control.

The treated animals received a single intraperitoneal administration of either the test substance or cyclophosphamide. The femoral marrow of groups treated with the test substance was prepared 16, 24 and 48 hours after administration. All negative and positive control animals were sacrificed after 24 hours. The doses of the test substance and the positive control, cyclophosphamide, were 50 and 20 mg/kg body weight, respectively.

The animals treated with the test substance showed symptoms of toxicity after administration. Two of fourty animals died before the end of the test due to the acute intraperitoneal toxicity of 50 mg/kg test substance.

There was an altered ratio between polychromatic and normochromatic erythrocytes.

Cyclophosphamide, the positive control, had a clear clastogenic effect, as is shown by the biologicaly relevant increase in polychromatic to normochromatic erythrocytes was not altered.

No indications of a clastogenic effect of the test substance were found after a single intraperitoneal treatment with 50 mg/kg body weight.